0001104659-17-072537.txt : 20171208 0001104659-17-072537.hdr.sgml : 20171208 20171208162911 ACCESSION NUMBER: 0001104659-17-072537 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171206 FILED AS OF DATE: 20171208 DATE AS OF CHANGE: 20171208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chan Barbara Y CENTRAL INDEX KEY: 0001676343 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17082 FILM NUMBER: 171247426 MAIL ADDRESS: STREET 1: C/O AEGERION PHARMACEUTICALS INC. STREET 2: ONE MAIN ST., SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NOVELION THERAPEUTICS INC. CENTRAL INDEX KEY: 0000827809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O NORTON ROSE FULBRIGHT STREET 2: 1800 - 510 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6B 0M3 BUSINESS PHONE: (877) 764-3131 MAIL ADDRESS: STREET 1: C/O NORTON ROSE FULBRIGHT STREET 2: 1800 - 510 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6B 0M3 FORMER COMPANY: FORMER CONFORMED NAME: QLT INC/BC DATE OF NAME CHANGE: 20000608 FORMER COMPANY: FORMER CONFORMED NAME: QLT PHOTO THERAPEUTICS INC DATE OF NAME CHANGE: 19960618 FORMER COMPANY: FORMER CONFORMED NAME: QUADRA LOGIC TECHNOLOGIES INC DATE OF NAME CHANGE: 19941201 4 1 a4.xml 4 X0306 4 2017-12-06 0 0000827809 NOVELION THERAPEUTICS INC. NVLN 0001676343 Chan Barbara Y C/O NOVELION THERAPEUTICS INC. 1800-510 WEST GEORGIA STREET VANCOUVER, BRITISH COLUMBIA A1 V6B OM3 BRITISH COLUMBIA, CANADA 0 1 0 0 See Remarks Common Shares 2017-12-06 4 F 0 1216 3.33 D 13784 D Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of 3,750 restricted stock units on December 6, 2017. This total includes 11,250 unvested restricted stock units which were granted on December 6, 2016 and were reported in Table II, as well as the shares settled after the tax withholding and vesting event described in footnote number 2. Each restricted stock unit represents a contingent right to receive one common share of the Issuer. President and Chief Accounting Officer of Aegerion Pharmaceuticals, Inc. /s/ Jennifer Fitzpatrick, attorney-in-fact 2017-12-08